Aktis Oncology, Inc. AKTS
Set alert
As of Nov 2, 10:54 AM ET
- YTD
- -36.63%
- 1 year
- -36.63%
- Open
- 16.01
- Prev close
- 15.93
- Mkt cap
- 788.13M
- Vol
- 156.27K
- Avg vol
- 361.49K
- EPS
- -1.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.00
- High
- 16.01
- Forward P/E
- -8.45
- Beta
- 0.00
- Short ratio
- 10.89
- Inst. own
- 73.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 22.96
- 200-d avg
- 21.42
- 1y target
- 35.39
News
2 weeks ago seekingalpha.com
Aktis Oncology: Padcev Is Building The Market It Wants
Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. AKTS has a cash runway into 2029, supported by $517.3M in cash and a $1.2B+…
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target
Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.
-
1 month ago benzinga.com
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1…
1 month ago globenewswire.com
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors Enrollment is ongoing in the Phase 1b BActinium-1…
1 month ago seekingalpha.com
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40
Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $40.
-
2 months ago benzinga.com
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
-
2 months ago benzinga.com
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
2 months ago investopedia.com
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
A pullback in the AI trade has created opportunities for bargain-hunting investors, according to analysts at Bank of America.
2 months ago benzinga.com
Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs
Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.
-
2 months ago benzinga.com
Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate
Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 98.03 percent increase over losses of…
2 months ago globenewswire.com
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
-
3 months ago benzinga.com
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33
JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises the price target from $30 to $33.
3 months ago benzinga.com
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's regular session. The market value of their outstanding shares is at $4.8 million. Seer (NASDAQ:SEER)…
4 months ago benzinga.com
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrades, visit analyst ratings page. Consider buying AKTS stock? Analysts weigh in.
4 months ago benzinga.com
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones gaining 100 points. Rezolve AI (RZLV) jumped 11.9%, and other stocks such as ALOY and FWRD also rose.
4 months ago seekingalpha.com
Aktis Oncology: Mini-Proteins With A Targeted Punch
Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly collaboration at $560M. The investment thesis hinges on the mini-protein platform targeting Nectin-4,…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 months ago globenewswire.com
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
5 months ago globenewswire.com
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
5 months ago fool.com
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
5 months ago globenewswire.com
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
6 months ago globenewswire.com
Aktis Oncology to Present at the BofA Securities Health Care Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
6 months ago globenewswire.com
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
6 months ago benzinga.com
This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday
Top analysts change outlook on Hyperfine Inc, Legence, and Aktis Oncology with Buy/Outperform ratings and price targets. See other analysts' views.
6 months ago seekingalpha.com
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting
Aktis Oncology is initiated with a "Buy" rating, driven by its innovative miniprotein radioconjugates targeting Nectin-4 and B7-H3 solid tumors. The company expects key catalysts: AKY-1189 phase 1b…
6 months ago zacks.com
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts…
6 months ago globenewswire.com
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
7 months ago globenewswire.com
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…
7 months ago benzinga.com
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst ratings page. Consider AKTS stock based on analyst views.
8 months ago globenewswire.com
Aktis Oncology to Present at Upcoming March Investor Conferences
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to…
8 months ago globenewswire.com
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to…
9 months ago benzinga.com
This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday
This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday
9 months ago 247wallst.com
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.
-
1 year ago benzinga.com
Crude Oil Down 1%; Webuy Global Shares Spike Higher
Crude Oil Down 1%; Webuy Global Shares Spike Higher
-
1 year ago benzinga.com
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Information Technology Stocks Moving In Thursday's Pre-Market Session
12 Information Technology Stocks Moving In Thursday's Pre-Market Session
-
2 years ago benzinga.com
12 Information Technology Stocks Moving In Tuesday's After-Market Session
12 Information Technology Stocks Moving In Tuesday's After-Market Session
-
2 years ago benzinga.com
12 Information Technology Stocks Moving In Tuesday's Intraday Session
12 Information Technology Stocks Moving In Tuesday's Intraday Session
-
2 years ago benzinga.com
12 Information Technology Stocks Moving In Friday's After-Market Session
12 Information Technology Stocks Moving In Friday's After-Market Session
-
2 years ago benzinga.com
12 Information Technology Stocks Moving In Thursday's Intraday Session
12 Information Technology Stocks Moving In Thursday's Intraday Session
-
2 years ago benzinga.com
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
-
2 years ago benzinga.com
Why JD.com Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Why JD.com Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
12 Information Technology Stocks Moving In Tuesday's Intraday Session
12 Information Technology Stocks Moving In Tuesday's Intraday Session
-
2 years ago benzinga.com
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
-
2 years ago benzinga.com
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
-
2 years ago benzinga.com
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
-
2 years ago benzinga.com
12 Information Technology Stocks Moving In Monday's After-Market Session
12 Information Technology Stocks Moving In Monday's After-Market Session